Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of LIK066 versus placebo or sitagliptin in type 2 diabetes mellitus
2012-005793-63Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in type 2 diabetes mellitus (T2DM) (9 arms), sponsored by Novartis. Primary endpoint: Primary endpoint: Change from baseline in HbA1c at 12 weeks. Started Apr 2013; status: terminated.
02
Drugs
licogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-005793-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005793-63.